297 related articles for article (PubMed ID: 17062714)
1. Treatment for myeloma bone disease.
Yeh HS; Berenson JR
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
[TBL] [Abstract][Full Text] [Related]
2. Myeloma bone disease and treatment options.
Yeh HS; Berenson JR
Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
[TBL] [Abstract][Full Text] [Related]
3. Myeloma bone disease.
Berenson JR
Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in the management of myeloma bone disease.
Berenson JR
Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
[TBL] [Abstract][Full Text] [Related]
5. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
[TBL] [Abstract][Full Text] [Related]
6. Advances in the biology and treatment of bone disease in multiple myeloma.
Raje N; Roodman GD
Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
[TBL] [Abstract][Full Text] [Related]
7. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
11. Emerging strategies in bone health management for the adjuvant patient.
Coleman RE
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
[TBL] [Abstract][Full Text] [Related]
12. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in multiple myeloma.
Apperley JF; Croucher PI
Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
[TBL] [Abstract][Full Text] [Related]
14. Advances in multiple myeloma and spine disease.
Latif T; Hussein MA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):228-33. PubMed ID: 16354328
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
17. Bone disease in myeloma.
Berenson JR
Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
19. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
20. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
